Logo image of OCUP

OCUPHIRE PHARMA INC (OCUP) Stock Fundamental Analysis

NASDAQ:OCUP - Nasdaq - US67577R1023 - Common Stock - Currency: USD

1.17  -0.16 (-12.03%)

After market: 1.1601 -0.01 (-0.85%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to OCUP. OCUP was compared to 198 industry peers in the Pharmaceuticals industry. While OCUP has a great health rating, there are worries on its profitability. OCUP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OCUP has reported negative net income.
OCUP had a negative operating cash flow in the past year.
In the past 5 years OCUP reported 4 times negative net income.
OCUP had negative operating cash flow in 4 of the past 5 years.
OCUP Yearly Net Income VS EBIT VS OCF VS FCFOCUP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -31.46%, OCUP is in line with its industry, outperforming 54.64% of the companies in the same industry.
OCUP has a better Return On Equity (-34.71%) than 65.46% of its industry peers.
Industry RankSector Rank
ROA -31.46%
ROE -34.71%
ROIC N/A
ROA(3y)-66.45%
ROA(5y)-81.05%
ROE(3y)-78.82%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OCUP Yearly ROA, ROE, ROICOCUP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200

1.3 Margins

OCUP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OCUP Yearly Profit, Operating, Gross MarginsOCUP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K

More info and screens

8

2. Health

2.1 Basic Checks

OCUP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OCUP has more shares outstanding
OCUP has more shares outstanding than it did 5 years ago.
There is no outstanding debt for OCUP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
OCUP Yearly Shares OutstandingOCUP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
OCUP Yearly Total Debt VS Total AssetsOCUP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

An Altman-Z score of 1.82 indicates that OCUP is not a great score, but indicates only limited risk for bankruptcy at the moment.
OCUP has a better Altman-Z score (1.82) than 64.43% of its industry peers.
There is no outstanding debt for OCUP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.82
ROIC/WACCN/A
WACC9.1%
OCUP Yearly LT Debt VS Equity VS FCFOCUP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M

2.3 Liquidity

OCUP has a Current Ratio of 10.68. This indicates that OCUP is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 10.68, OCUP belongs to the best of the industry, outperforming 80.93% of the companies in the same industry.
A Quick Ratio of 10.68 indicates that OCUP has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 10.68, OCUP belongs to the top of the industry, outperforming 80.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.68
Quick Ratio 10.68
OCUP Yearly Current Assets VS Current LiabilitesOCUP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for OCUP have decreased strongly by -165.48% in the last year.
OCUP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -63.65%.
EPS 1Y (TTM)-165.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-63.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-69.73%

3.2 Future

OCUP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.62% yearly.
OCUP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 42.52% yearly.
EPS Next Y-85.94%
EPS Next 2Y-38.1%
EPS Next 3Y10.72%
EPS Next 5Y41.62%
Revenue Next Year-44.06%
Revenue Next 2Y-18.88%
Revenue Next 3Y16.43%
Revenue Next 5Y42.52%

3.3 Evolution

OCUP Yearly Revenue VS EstimatesOCUP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M 200M
OCUP Yearly EPS VS EstimatesOCUP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OCUP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OCUP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCUP Price Earnings VS Forward Price EarningsOCUP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCUP Per share dataOCUP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-38.1%
EPS Next 3Y10.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OCUP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OCUPHIRE PHARMA INC

NASDAQ:OCUP (10/23/2024, 8:00:03 PM)

After market: 1.1601 -0.01 (-0.85%)

1.17

-0.16 (-12.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2024-08-13/bmo
Earnings (Next)11-08 2024-11-08/bmo
Inst Owners9.66%
Inst Owner Change-1.32%
Ins Owners8.94%
Ins Owner Change0%
Market Cap30.65M
Analysts82.22
Price Target17.09 (1360.68%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-63.76%
Min EPS beat(2)-112.17%
Max EPS beat(2)-15.34%
EPS beat(4)1
Avg EPS beat(4)-52.32%
Min EPS beat(4)-292.16%
Max EPS beat(4)210.41%
EPS beat(8)3
Avg EPS beat(8)-25.79%
EPS beat(12)6
Avg EPS beat(12)-13.86%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-58.11%
Min Revenue beat(2)-60.55%
Max Revenue beat(2)-55.68%
Revenue beat(4)1
Avg Revenue beat(4)25.38%
Min Revenue beat(4)-69.01%
Max Revenue beat(4)286.75%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.84%
EPS NQ rev (1m)0.98%
EPS NQ rev (3m)-11.4%
EPS NY rev (1m)0.85%
EPS NY rev (3m)-25.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20.47%
Revenue NY rev (1m)0.7%
Revenue NY rev (3m)-22.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.86
P/FCF N/A
P/OCF N/A
P/B 0.75
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.63
BVpS1.55
TBVpS1.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.46%
ROE -34.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.45%
ROA(5y)-81.05%
ROE(3y)-78.82%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.68
Quick Ratio 10.68
Altman-Z 1.82
F-Score3
WACC9.1%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-165.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-85.94%
EPS Next 2Y-38.1%
EPS Next 3Y10.72%
EPS Next 5Y41.62%
Revenue 1Y (TTM)-63.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-69.73%
Revenue Next Year-44.06%
Revenue Next 2Y-18.88%
Revenue Next 3Y16.43%
Revenue Next 5Y42.52%
EBIT growth 1Y-175.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-202.74%
EBIT Next 3Y73.4%
EBIT Next 5Y91.81%
FCF growth 1Y40.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.34%
OCF growth 3YN/A
OCF growth 5YN/A